COMPANY

Whitehawk Therapeutics

HQ: Morristown, NJ source · whitehawktx.com ↗ · Mid-Atlantic

Whitehawk Therapeutics develops cancer therapies by pairing established tumor biology targets with advanced technologies. From company website Source · Oct 12, 2026

Keywords: tumor Platinum Resistant Ovarian Cancer Endometrial Cancer Ovarian Cancer Ovarian Cancer Metastatic Ovarian Cancer Metastatic Recurrent Non-squamous EGFR Wt NSCLC HWK-007

Location: Morristown, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$187.5MRaised (2 yrs)2Trials (company is sponsor)

Timeline

May 21, 2026 Partnership Partnership / licensing announced May 21, 2026. Source: SEC filing. source ↗
May 13, 2026 Raise Private placement: $87.5M (total, as published), announced May 13, 2026. Source: SEC filing. source ↗
Mar 15, 2026 Trial start Phase 1: A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. source ↗
Dec 19, 2025 Trial start Phase 1: Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors source ↗
Mar 4, 2025 Raise Private placement: $100M (total, as published), announced Mar 4, 2025. Source: SEC filing. source ↗
Dec 19, 2024 Partnership Partnership / licensing: upfront $44M paid by the company to the licensor (in-licensing; not money received), announced Dec 19, 2024. Source: SEC filing. source ↗

Upcoming milestones

2028-02 (ESTIMATED) · Phase 1 · A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. · NCT07470853
2028-10 (ESTIMATED) · Phase 1 · Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors · NCT07444814

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $187.5M. Last 2 years.

May 13, 2026 Private placement: $87.5M (total, as published), announced May 13, 2026. Source: SEC filing. source ↗
Mar 4, 2025 Private placement: $100M (total, as published), announced Mar 4, 2025. Source: SEC filing. source ↗
May 21, 2026 Partnership / licensing announced May 21, 2026. Source: SEC filing. source ↗
Dec 19, 2024 Partnership / licensing: upfront $44M paid by the company to the licensor (in-licensing; not money received), announced Dec 19, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07470853	A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.	Phase 1	Recruiting	Mar 15, 2026	2028-02 (estimated)
NCT07444814	Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Dec 19, 2025	2028-10 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-03-18 Raise Private raise (SEC Form D): $100.0M sold; issuer “Aadi Bioscience, Inc.”. Verified from the SEC filing. SEC filing ↗